Cargando…

Drugs for the overactive bladder: are there differences in persistence and compliance?

Detalles Bibliográficos
Autor principal:	Andersson, Karl-Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2017
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5503948/ https://www.ncbi.nlm.nih.gov/pubmed/28725606 http://dx.doi.org/10.21037/tau.2017.03.90

Ejemplares similares

Persistence and compliance with medication management in the treatment of overactive bladder
por: Kim, Tae Heon, et al.
Publicado: (2016)

Drug therapy of overactive bladder - What is coming next?
por: Andersson, Karl-Erik
Publicado: (2015)

Common theme for drugs effective in overactive bladder treatment: Inhibition of afferent signaling from the bladder
por: Hood, Brandy, et al.
Publicado: (2013)

Overactive bladder: strategies to ensure treatment compliance and adherence
por: Dhaliwal, Prabhpreet, et al.
Publicado: (2016)

New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA
por: Andersson, Karl-Erik
Publicado: (2013)

Overactive Bladder: Pathophysiology, Diagnostics, and Therapies
por: Heesakkers, John P. F. A., et al.
Publicado: (2011)

Deterioration of bladder compliance after botulinum toxin A injection and discontinuation of medication for overactive bladder
por: Wada, Naoki, et al.
Publicado: (2022)

Long-term adherence to clinical therapy of overactive bladder
por: Drake, Marcus John
Publicado: (2017)

Urodynamic efficacy of fesoterodine for the treatment of neurogenic detrusor overactivity and/or low compliance bladder
por: Kaga, Kanya, et al.
Publicado: (2020)

Overactive bladder
por: Wallace, Karen M., et al.
Publicado: (2015)

Future directions in overactive bladder treatment: Personalized medicine can be applied?
por: Lee, Kyu-Sung
Publicado: (2015)

Gene Therapy for Overactive Bladder: A Review of BK-Channel α-Subunit Gene Transfer
por: Andersson, Karl-Erik, et al.
Publicado: (2021)

A watershed paper for surgical cure of overactive bladder and nocturia
por: Petros, Peter
Publicado: (2021)

Postmenopausal overactive bladder
por: Tomaszewski, Jacek
Publicado: (2014)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
por: Al-Ghazo, Mohammed A., et al.
Publicado: (2011)

Increased detrusor collagen is associated with detrusor overactivity and decreased bladder compliance in men with benign prostatic obstruction
por: Bellucci, Carlos H.S., et al.
Publicado: (2017)

Differences in the Urinary Microbiome of Patients with Overactive Bladder Syndrome with and without Detrusor Overactivity on Urodynamic Measurements
por: Javan Balegh Marand, Aida, et al.
Publicado: (2023)

Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment
por: Mahajan, Rajiv, et al.
Publicado: (2011)

Pharmacologic management of overactive bladder
por: Lam, Sum, et al.
Publicado: (2007)

Medical management of overactive bladder
por: Ubee, Sarvpreet S., et al.
Publicado: (2010)

Overactive bladder in the vulnerable elderly
por: Wolff, Gillian F, et al.
Publicado: (2014)

Urinary biomarkers of overactive bladder
por: Tian, Xiao-Jun, et al.
Publicado: (2019)

Review of the epidemiology of overactive bladder
por: Eapen, Renu S, et al.
Publicado: (2016)

Impact of depression on overactive bladder
por: Kawahara, Takashi, et al.
Publicado: (2020)

Current pharmacotherapy of overactive bladder
por: Kreydin, Evgenyi I., et al.
Publicado: (2021)

Update on the management of overactive bladder
por: Fontaine, Christina, et al.
Publicado: (2021)

Mediterranean Diet and Overactive Bladder
por: Bozkurt, Yunus Erol, et al.
Publicado: (2022)

Telemedicine in Overactive Bladder Syndrome
por: Jericevic, Dora, et al.
Publicado: (2023)

Updates of Overactive Bladder in Pediatrics
por: Shim, Jisung, et al.
Publicado: (2023)

Urodynamic and Bladder Diary Factors Predict Overactive Bladder-wet in Women: A Comparison With Overactive Bladder-dry
por: Hsiao, Sheng-Mou, et al.
Publicado: (2019)

Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
por: Chen, Sheng-Fu, et al.
Publicado: (2020)

Evaluation of real-world persistence of propiverine and trospium chloride in treatment of overactive bladder in Germany
por: Murgas, Sandra, et al.
Publicado: (2019)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

Updating the evidence on drugs to treat overactive bladder: a systematic review
por: Hsu, Frances C., et al.
Publicado: (2019)

Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry study
por: Carlson, Kevin V., et al.
Publicado: (2021)

Overactive bladder with urodynamic study-induced bladder pain: An overactive bladder subtype with symptoms similar to those of interstitial cystitis/painful bladder syndrome
por: Mu, Hsueh-Yu, et al.
Publicado: (2023)

Coexisting overactive–underactive bladder and detrusor overactivity–underactivity in pelvic organ prolapse
por: Frigerio, Matteo, et al.
Publicado: (2022)

The surgical management of the refractory overactive bladder
por: Vasdev, Nikhil, et al.
Publicado: (2010)

Recent advances in management of bladder overactivity
por: Smith, Ariana L, et al.
Publicado: (2010)

Transdermal oxybutynin in the treatment of overactive bladder
por: Davila, G Willy
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_e3uq3ff87968e9cdnp6olqhjqo